May 15, 2019 CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma Learn More
May 13, 2019 Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma Learn More
May 6, 2019 Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update Learn More
Mar 19, 2019 FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients Learn More